Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EMA Emera Inc.

交易中 12-15 11:32:26 EST

47.93

+0.01

+0.02%

最高48.27	最低47.92	成交量4.54万
今开48.11	昨收47.92	日振幅0.73%
总市值144.63亿	流通市值143.25亿	总股本3.02亿
成交额218.47万	换手率0.02%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":47.93,"timestamp":1765816311946,"preClose":47.92,"halted":0,"volume":45371,"delay":0,"floatShares":298863171,"shares":301745499,"eps":2.652318,"marketStatus":"交易中","change":0.01,"latestTime":"12-15 11:32:26 EST","open":48.11,"high":48.27,"low":47.92,"amount":2184743.41106,"amplitude":0.007304,"askPrice":47.94,"askSize":106,"bidPrice":47.92,"bidSize":126,"shortable":3,"etf":0,"ttmEps":2.652318,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":47.92,"dividendRate":0.043788,"postHourTrading":{"tag":"盘后","latestPrice":47.92,"preClose":47.92,"latestTime":"17:59 EST","volume":97753,"amount":4684110.567498,"timestamp":1765580358754},"volumeRatio":0.514254,"impliedVol":0.1149,"impliedVolPercentile":0.2321},"requestUrl":"/m/hq/s/EMA/tweets","defaultTab":"tweets","newsList":[{"id":"2589334696","title":"乐城引进帕西生长激素注射液 为GHD患儿提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334696","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589334696?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:40","pubTimestamp":1765190402,"startTime":"0","endTime":"0","summary":"今年1月，诺和诺德长效生长激素——帕西生长激素注射液作为临床急需药物被引入乐城博鳌未来医院(海南省妇女儿童医学中心乐城分院)，并于5月正式投入临床。目前，该药已惠及20余例年龄在4.5至14.5岁之间的生长激素缺乏症(GHD)患儿，为我国GHD患儿提供了新的治疗选择。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208183409_27282.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BMG7P694.USD","IE00BD4GTV84.USD","BK4081","IE00BMG7P819.SGD","IE00BD4GTT62.SGD","BK4588","BK4585","IE00BMG7P587.USD","BK4208","EMA","IE00BD4GTW91.USD","PEG","LU2346227817.USD","IE00BMG7P926.USD"],"gpt_icon":0},{"id":"2589519008","title":"港股异动 | 亚盛医药-B(06855)涨超6% 耐立克®POLARIS-1研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589519008?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","EMA","BK4081","06855","BK4139","BK1574"],"gpt_icon":0},{"id":"2589985521","title":"亚盛医药-B(06855)耐立克®一线治疗Ph+ ALL的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589985521?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","EMA","BK4588","LU1571399168.USD","BK4134","BK4585","III","BK4081","LU1699723380.USD","BK4533","AAPG","BK4139","LU2355687059.USD","BK1574","LU0985320562.USD","06855","ALL","BK4107"],"gpt_icon":0},{"id":"2579814485","title":"透视瑞博生物赴港之旅：管线布局均衡丰富，具备“中国版Alnylam”稀缺特质","url":"https://stock-news.laohu8.com/highlight/detail?id=2579814485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579814485?lang=zh_cn&edition=full","pubTime":"2025-10-31 09:08","pubTimestamp":1761872935,"startTime":"0","endTime":"0","summary":"管线布局均衡丰富，核心产品“高价值”释放在即2024年5月31日，全球RNAi疗法龙头Alnylam市值正式超越Moderna，彼时Alnylam的市值约为550亿美元，而Moderna的市值则跌至约530亿美元。从整体布局特点来看，瑞博生物产品管线布局丰富且均衡，核心产品管线主要聚焦在心血管、代谢及肾脏疾病这一类大病种、大市场,商业天花板极高。据悉，2023年12月以来，瑞博生物先后与齐鲁制药、勃林格殷格翰签订合作及许可协议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","HDV","BK4081","EMA"],"gpt_icon":0},{"id":"2577759511","title":"瑞博生物治疗丁型肝炎病毒感染的小核酸药物RBD1016获EMA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2577759511","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577759511?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:44","pubTimestamp":1761295484,"startTime":"0","endTime":"0","summary":"EMA的孤儿药资格认定旨在鼓励在欧盟发病率低于万分之五、导致严重威胁生命或慢性衰竭性罕见病的在研疗法。瑞博生物自主研发的RiboGalSTARTM肝靶向递送平台的安全性、有效性和长效性已通过多项临床研究得以验证，其中包括用于治疗HDV适应症的RBD1016，目前该药物正在全球同步推进乙肝和丁肝的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物治疗丁型肝炎病毒感染的小核酸药物RBD1016获EMA孤儿药资格认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2576055837","title":"EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576055837?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:29","pubTimestamp":1760707780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在本周召开的会议上，欧洲药品管理局的专家小组对赛诺菲与Insmed的两款新药做出了推荐在该地区上市的积极意见。除了推荐新药获批外，该委员会还否决了赛诺菲的一款新药，并推荐了8项新的药品适应症扩展申请。赛诺菲表示，这一决定基于该公司关键的LUNA 3期临床试验。该公司表示，CHMP的这一决定令人失望，并将寻求对该决定进行重新审查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0889565916.HKD","BK4585","BK4139","IE00BFXG1179.USD","BK4588","BK4081","LU0053671581.USD","LU0109394709.USD","LU0320765992.SGD","INSM","EMA","SNY"],"gpt_icon":0},{"id":"2574545435","title":"马斯克给出“AI能源”解决方案：电网夜间储能、白天放电，将使美国电力产出翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2574545435","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574545435?lang=zh_cn&edition=full","pubTime":"2025-10-11 14:29","pubTimestamp":1760164181,"startTime":"0","endTime":"0","summary":"马斯克近日提出通过大规模部署工业级电池储能系统，可将美国电网有效发电能力提升一倍，为解决AI能源危机提供清晰路径。","market":"us","thumbnail":"https://static.tigerbbs.com/ee293fe5629ee0ea9f80cfafff4b2fa4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ee293fe5629ee0ea9f80cfafff4b2fa4"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3756998","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3756998","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["CMS","EMA","D","SO","WEC","OKLO","DUK","ED","VIA"],"gpt_icon":1},{"id":"2572522557","title":"选年薪百万还是985学历？研究发现收入管开心，教育管健康，两者在中上水平后均趋缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2572522557","media":"尹哥聊基因","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572522557?lang=zh_cn&edition=full","pubTime":"2025-10-03 08:02","pubTimestamp":1759449720,"startTime":"0","endTime":"0","summary":"最近社交媒体上有一个热门话题：“给你一百万，或者一个985名校的学历，你会选哪个？”04社区层面影响接着，研究者将分析扩展至社区层面，考察一个地区的平均收入和教育水平是否影响其中个体的健康与幸福。研究发现，钱和学历的“边际效益”会递减。△ 主观收入、教育和结果衡量之间的非线性关系06小结综上，这项研究告诉我们：收入管“开心”，教育管“健康”，换句话说，钱能买来今天的笑容，但","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-03/doc-infsqhux7979650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4081","BK4096","SES","BK4603","EMA"],"gpt_icon":0},{"id":"2570857812","title":"路虎“卫士Defender运动版”纯电入门SUV路测图曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2570857812","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570857812?lang=zh_cn&edition=full","pubTime":"2025-09-27 11:00","pubTimestamp":1758942013,"startTime":"0","endTime":"0","summary":"IT之家 9 月 27 日消息，汽车媒体 CarScoops 今天发布博文，分享了一组在欧洲抓拍到的照片，展示了捷豹路虎正在测试的“卫士运动版”入门 SUV，预计于 2027 年面世。该 SUV 基于电动模块化架构平台，采用 800 伏充电架构，是捷豹路虎电动化蓝图中的关键产品。该媒体预估路虎增强户外探险场景，将提供环绕式玻璃区域、悬浮式车顶及双色涂装选项，并可搭配多种定制化配件。该媒体推测为延续路虎的越野基因，车辆将搭载双电机组合，具备先进全轮驱动能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8mzC8GZZNzz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2568434774","title":"IIgANN 2025：耐赋康®最新真实世界研究证实长期对因治疗持续展现良好有效性与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2568434774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568434774?lang=zh_cn&edition=full","pubTime":"2025-09-18 07:43","pubTimestamp":1758152620,"startTime":"0","endTime":"0","summary":"为进一步探索在完成9个月治疗后耐赋康的延长用药价值，此次在IIgANN 2025上展示的回顾性研究1旨在评估12个月布地奈德肠溶胶囊治疗在IgA肾病患者中的真实世界疗效和安全性，并与传统治疗进行比较。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","EMA","01952","BK1574","BK1161","BK4081"],"gpt_icon":0},{"id":"2565565274","title":"欧洲药品管理局（EMA）：诺和诺德（Novo Nordisk）将在2026年底前停止在欧盟/欧洲经济区（EEA）销售维格","url":"https://stock-news.laohu8.com/highlight/detail?id=2565565274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565565274?lang=zh_cn&edition=full","pubTime":"2025-09-05 21:38","pubTimestamp":1757079481,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FSXEmain","NVO","EMA","LU0154236417.USD","LU1093756325.SGD","FESXmain","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","EEA","BK4532","BK4007","BK4588","BK4599","IE00BZ1G4Q59.USD","BK4081"],"gpt_icon":0},{"id":"2560164615","title":"药明生物爱尔兰基地获EMA认证 助力创新生物药商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2560164615","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560164615?lang=zh_cn&edition=full","pubTime":"2025-08-19 17:14","pubTimestamp":1755594843,"startTime":"0","endTime":"0","summary":"药明生物宣布，其爱尔兰敦多克工厂正式通过欧洲药品管理局（EMA）审核，成为客户一款创新生物药的商业化生产基地。该基地凭借卓越的产能与质量控制，已获得多项国际资质认可，并在大规模工艺性能确认（PPQ）生产中保持100%的成功率。此次获批进一步巩固了药明生物在全球生物制药领域的领先地位，为欧洲市场提供更高效的商业化生产支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081917194994ecef6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081917194994ecef6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2560730829","title":"港股异动 | 亚盛医药-B(06855)高开逾4% 利生妥治疗中高危MDS III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2560730829","media":"智通财经","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560730829?lang=zh_cn&edition=full","pubTime":"2025-08-18 09:24","pubTimestamp":1755480288,"startTime":"0","endTime":"0","summary":"据悉，利生妥是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制 Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。利生妥为中国首个获批上市的国产原创Bcl-2抑制剂。截止本公告日期，利生妥也是国际上唯一正推进中高危MDS注册III期临床的Bcl-2抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4139","BK1574","BK4081","BK1161","BK4134","AAPG","06855","EMA"],"gpt_icon":0},{"id":"2560978538","title":"亚盛医药-B(06855)：利生妥®一线治疗中高危MDS患者的全球注册III期临床研究获美国FDA和欧洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2560978538","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560978538?lang=zh_cn&edition=full","pubTime":"2025-08-18 07:34","pubTimestamp":1755473685,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司自主研发的Bcl-2选择性抑制剂利沙托克拉联合阿扎胞苷一线治疗新诊断的中高危骨髓增生异常综合症患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。截止本公告日期，利生妥也是国际上唯一正推进中高危MDS注册III期临床的Bcl-2抑制剂。利生妥为中国首个获批上市的国产原创Bcl-2抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","EMA","BK4081","BK4134","III","06855","BK4139","BK1574"],"gpt_icon":0},{"id":"2559936877","title":"以诺康启动上市辅导；绿谷971再注册申请未获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2559936877","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559936877?lang=zh_cn&edition=full","pubTime":"2025-08-14 08:34","pubTimestamp":1755131649,"startTime":"0","endTime":"0","summary":"根据新闻稿，Brinsupri是首个获FDA批准用于NCFB的治疗方案。资本市场高端医疗器械企业以诺康启动上市辅导8月12日，证监会网站披露，以诺康医疗科技（苏州）股份有限公司在江苏证监局上市辅导备案，辅导机构为华泰证券。截止本公告日，博灵脑机产品尚未正式上市，仅因与科研机构合作而销售少量产品。舆情预警绿谷971再注册申请未获批准2025年8月12日，国家药监局政务服务门户网站发布通知，绿谷制药的甘露特钠胶囊再注册申请未获批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814083654a6e4c64a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814083654a6e4c64a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","LU1223082519.USD","LU1223083913.SGD","AD","BK4017","LU1223082196.USD","BK4081","CDE"],"gpt_icon":0},{"id":"2557794359","title":"港股异动 | 复宏汉霖(02696)再涨超5% H药汉斯状进入印度市场 HLX14此前获EMA积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2557794359","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557794359?lang=zh_cn&edition=full","pubTime":"2025-08-05 11:22","pubTimestamp":1754364167,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超5%，截至发稿，涨5.28%，报70.8港元，成交额1515.65万港元。消息面上，7月31日，复宏汉霖宣布，其自主研发的抗PD-1单抗H药已完成首批面向印度市场的发货。至此，汉斯状已在近40个国家和地区获批。此外，复宏汉霖近日公布，公司自主研发的Prolia与Xgeva生物类似药HLX14获得欧洲药品管理局人用药品委员会的积极审评意见，推荐批准其上市许可申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","BK4081","MNDmain","BK1161","02696"],"gpt_icon":0},{"id":"2555846748","title":"百济神州BGB-16673获EMA优先药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2555846748","media":"DoNews","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555846748?lang=zh_cn&edition=full","pubTime":"2025-07-31 18:45","pubTimestamp":1753958703,"startTime":"0","endTime":"0","summary":"2025年7月31日，百济神州宣布，欧洲药品管理局（EMA）已授予其在研布鲁顿氏酪氨酸激酶（BTK）降解剂BGB-16673优先药物（PRIME）认定，用于治疗既往接受过BTK抑制剂治疗的华氏巨球蛋白血症（WM）患者。EMA人用药品委员会（CHMP）还就该药物的欧盟孤儿药资格认定申请发布了积极意见，最终决定预计几周后公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118482794c605e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118482794c605e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4526","BK4139","ONC","BGB","EMA","BK4081"],"gpt_icon":0},{"id":"2554877836","title":"复宏汉霖(02696)：地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877836?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:17","pubTimestamp":1753697873,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX14获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use，“CHMP”)积极审评意见，推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会(European Commission，“EC”)，EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准，HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","EMA","CHMP","BK1574","BK4087","BK4081","09939","BK1161","159938","02696"],"gpt_icon":0},{"id":"2551145456","title":"百奥泰BAT2506注射液上市许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2551145456","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551145456?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:53","pubTimestamp":1752652394,"startTime":"0","endTime":"0","summary":"7月16日，百奥泰发布公告，近日收到BAT2506注射液生物制品许可申请获得美国FDA受理的通知。公告中提到，BAT2506的原研药为美国强生公司的Simponi，根据强生公司2024年年度报告，Simponi2024年在全球的销售额为21.9亿美元。公司已在全球多个区域开展BAT2506的商业化进程，并获得中国NMPA、美国FDA、欧洲EMA、巴西ANVISA的上市许可申请受理。2025年一季度，百奥泰实现收入2.07亿元，归母净利润-9333万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161556269544908d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161556269544908d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2552127649","title":"7月15日技术分析报告：现货黄金、WTI原油期货","url":"https://stock-news.laohu8.com/highlight/detail?id=2552127649","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552127649?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:47","pubTimestamp":1752644820,"startTime":"0","endTime":"0","summary":"本文汇总Economies.com的分析师今日最新观点，包括现货黄金、WTI原油期货等多个品种！现货黄金价格获得更多支撑Economies.com的分析师今日最新观点：现货黄金在上个交易日上涨，得益于其倚靠EMA50均线支撑，这有助于减缓之前的看跌浪潮并为价格企稳提供机会。WTI原油期货试图收复部分前期跌幅Economies.com的分析师今日最新观点：WTI原油期货在上个交易日小幅上涨，试图收复部分前期跌幅。尽管出现上涨，但油价仍面临明显技术压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717013617a6adf1c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717013617a6adf1c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","UCO","BK4585","BK4081","BK4570","SCO","USO","EMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.0246},{"period":"6month","weight":0.0618},{"period":"1year","weight":0.0583},{"period":"ytd","weight":0.0583}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Incorporated是一家北美能源服务提供商，成立于1998年7月23日，拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州，另外还在加拿大大西洋省、新墨西哥州和加勒比地区开展业务。Emera总部位于新斯科舍省哈利法克斯。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}